220
Participants
Start Date
April 30, 2012
Primary Completion Date
October 31, 2013
Study Completion Date
April 30, 2014
Idelalisib
Idelalisib 150 mg tablet administered orally twice daily
Rituximab
Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m\^2, and 500 mg/m\^2 thereafter
Placebo to match idelalisib
Placebo to match idelalisib administered orally twice daily
Gemeinschaftspraxis Hämatologie-Onkologie, Dresden
Ospedale Oncologico Regionale A. Businco, Cagliari
Weill Cornell Medical College, New York
Columbia University Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino
Long Island Jewish Medical Center, New Hyde Park
Georgetown University Medical Center Lombardi Cancer Center, Washington D.C.
Ospedale San Raffaele S.r.l., Milan
Virginia Cancer Specialists, PC, Fairfax
Oncology and Hematology Associates of Southwest Virginia, Inc, Roanoke
Cancer Centers of the Carolinas, Greenville
Winship Cancer Institute at Emory University, Atlanta
Hopital Purpan, Toulouse
University of Florida, Gainesville
Collaborative Medical Research Corporation, Boynton Beach
Collaborative Research Group LLC, Boynton Beach
Florida Cancer Specialists, St. Petersburg
Florida Cancer Specialists, Fort Myers
Hôpital Pontchaillou, Rennes
Clearview Cancer Institute, Huntsville
Sarah Cannon Cancer Center, Nashville
Universitätsklinikum Köln, Cologne
Medical College of Wisconsin, Milwaukee
Centre Hospitalier Régional Universitaire de Lille (CHRU), Lille
Northwestern University, Chicago
Hämatologische/Onkologische Gemeinschaftspraxis Dr. Peter Schmidt / Dr. Holger Klaproth, Neunkirchen
Hôpital Emile Muller, Mulhouse
Centre Hospitalier Lyon Sud, Pierre-Bénite
Stauferklinikum Schwäb. Gmünd, Mutlangen
Centre Henri Becquerel, Rouen
Texas Oncology, P.A., Fort Worth
M.D. Anderson Cancer Center, Houston
Cancer Care Network of South Texas, San Antonio
Rocky Mountain Blood and Marrow Transplant Program, Denver
Rocky Mountain Cancer Center, Denver
Arizona Oncology Associates, Tucson
Universitätsklinikum Ulm, Ulm
UCLA, Santa Monica
Internistische Gemeinschaftspraxis, Erlangen
University of California, San Diego- Moores Cancer Center, La Jolla
Ventura County Hematology Oncology Specialists, Oxnard
Hôpital Henri Mondor, Créteil
Stanford Cancer Center, Stanford
Northwest Cancer Specialists, PC, Tualatin
Willamette Valley Cancer Center, Springfield
Yakima Valley Memorial Hospital / North Star Lodge, Yakima
Hackensack University Medical Center, Hackensack
Hematology Oncology Associates of Northern New Jersey, Morristown
Seattle Cancer Care Alliance, Seattle
Royal Bournemouth Hospital, Bournemouth
Addenbrooke's Hospital, Cambridge
University Hospital of Wales, Cardiff
Castle Hill Hospital, Cottingham
Dorset County Hospital, Dorchester
Western General Hospital, Edinburgh
Northwick Park Hospital, Harrow
St James's University Hospital, Leeds
Royal Liverpool University Hospital, Liverpool
King's College Hospital, London
Hammersmith Hospital, London
Sarah Cannon Research Institute UK, London
Freeman Hospital, Newcastle upon Tyne
Princess Royal University Hospital, Orpington
Salisbury District Hospital, Salisbury
Southampton General Hospital, Southampton
Royal Marsden Hospital, Sutton
Great Western Hospital, Swindon
Torbay District General Hospital, Torquay
Royal Cornwall Hospital, Truro
New Cross Hospital, Wolverhampton
Yeovil District Hospital, Yeovil
Lead Sponsor
Gilead Sciences
INDUSTRY